ORCL Research Update — August 27, 2026 (Updated)
Updated Thesis
Oracle sells mission-critical database, enterprise applications, cloud infrastructure and industry software, supported by embedded customer relationships, switching costs and a broad enterprise and public-sector installed base. Business momentum is strong: revenue grew 20.6% and earnings grew 25.6% year over year in the most recent quarter, while FY2026 cloud revenue rose 39% to $34.0 billion and OCI IaaS revenue rose 77% to $18.1 billion. TTM profitability remains robust, with 65.8% gross margin, 30.8% operating margin, 25.4% net margin and 50.6% ROE, but the infrastructure buildout has impaired cash generation, producing negative $8.23 of free cash flow per share after $55.7 billion of FY2026 capex.
The investment grade as of this refresh is B — solid business quality. Medium-tier business, fair-tier valuation with 22.0% upside to $198.33 fair value, but financing and data-center execution risk temper conviction.
Grade Change
In this research cycle, the investment grade for Oracle Corporation moved from C to B. Medium-tier business, fair-tier valuation with 22.0% upside to $198.33 fair value, but financing and data-center execution risk temper conviction.
Key Metrics at a Glance
- Revenue growth: +20.6% year over year
- Net margin: 25.4%
- Fair value upside: +22.0% to our estimate of $198
Current price: $162.52
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Oracle Corporation remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full ORCL research →](/stocks/ORCL)